[music] [applause] health. What does good health mean anyways. What does it mean to every single one of us.I invite you all to think about that and maybe revisit your thoughts at the end of this talk and see if anything has changed for you. In preparation for this talk, Kathy and I asked a bunch of people what good health meant to all of them. And we really heard everything from I just want to be sick to I want to be injuryfree so I can run a marathon to I really just want to have peace of mind.So clearly t ...

Group 1 - The article does not provide any specific content related to a company or industry [1]

Veracyte (VCYT) 2025 Conference Summary Company Overview - **Company**: Veracyte, a leader in molecular diagnostics focused on cancer care [3][4] - **Core Products**: Afirma (thyroid diagnostics) and Decipher (prostate cancer prognosis) [5][6] Industry Insights - **Market Dynamics**: The cancer diagnostics market is expanding, with Veracyte aiming to serve patients globally, not just in the U.S. [3][4] - **Patient Impact**: Over 600,000 patients served to date, with significant clinical evidence supporting the utility of their tests [5][6] Financial Performance - **2024 Performance**: Achieved 28% testing revenue growth and a 20.6% adjusted EBITDA margin [5][19] - **Q1 2025 Performance**: Continued momentum with 19% testing revenue growth, marking the eleventh consecutive quarter of over 20% testing volume growth [6][18] - **Revenue Composition**: Decipher and Afirma accounted for 95% of total revenue in 2024 [6] Product Development and Pipeline - **Decipher Growth**: Over 275,000 patients tested, with a 45% CAGR from 2019 to 2024; aims for 80% market penetration [7][8] - **Afirma Updates**: Over 350,000 patients tested, with 60% avoiding unnecessary surgeries; expects high single-digit revenue growth [10][11] - **New Products**: Prosigna for breast cancer and MRD tests for muscle invasive bladder cancer are in development [13][15] Market Expansion - **Geographic Strategy**: Plans to launch tests in Europe, targeting HR positive breast cancer and prostate cancer markets [16][17] - **Innovative Solutions**: Development of the Percepta nasal swab for lung cancer detection, addressing a significant market need [17] Competitive Landscape - **MRD Competition**: Acknowledges competition but emphasizes differentiation through a whole genome approach and existing channels [31][34] - **Market Potential**: The MRD market is large, and Veracyte aims to carve out a significant share despite being a late entrant [32][34] Future Outlook - **2025 Guidance**: Anticipates 12% to 15% testing revenue growth for the full year, with adjusted EBITDA guidance raised to 22.5% [19][20] - **Long-term Goals**: Focused on achieving a 25% adjusted EBITDA margin and expanding product offerings [20][34] Key Takeaways - **Investor Perception**: The growth potential of pipeline products like MRD and Prosigna may not be fully recognized by investors [22][24] - **Capital Allocation**: Actively assessing M&A opportunities, with a high bar for potential targets [26][28] - **Resource Management**: Internal prioritization of resources is a challenge due to numerous growth opportunities [29]